ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report - Scorecard - MDSpire
Advertisement
ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report
Clinical Scorecard: Precision Therapy Utilizing ctDNA for Trastuzumab Deruxtecan and Pyrotinib in a Case of Brain Metastases from HER2-Positive Breast Cancer
At a Glance
Category
Detail
Condition
Key Mechanisms
Circulating tumor DNA (ctDNA) monitoring for disease activity and genomic profiling for resistance mechanisms.
Target Population
Care Setting
Key Highlights
Brain metastases occur in 30-55% of patients with HER2-positive metastatic breast cancer.
ctDNA monitoring detected disease activity earlier than conventional imaging.
Combination therapy with trastuzumab deruxtecan and pyrotinib achieved intracranial disease control for 17 months.
Genomic profiling revealed alterations such as MET amplification and HER2 V777L mutation.
Guideline-Based Recommendations
Diagnosis
Utilize comprehensive genomic profiling at diagnosis for HER2-positive breast cancer.
Management
Consider ctDNA monitoring to inform treatment adaptations.
Monitoring & Follow-up
Implement serial ctDNA monitoring for early detection of disease activity.
Risks
Monitor for drug-induced hepatotoxicity and manage with dose modifications.
Patient & Prescribing Data
Young women with HER2-positive metastatic breast cancer, particularly during pregnancy.
Combination therapy with trastuzumab deruxtecan and pyrotinib can be effective in managing brain metastases.
Clinical Best Practices
Incorporate ctDNA monitoring into treatment decision-making.
Utilize multidisciplinary teams for complex cases involving pregnancy and cancer.
